Aytu patents expiration
1. Karbinal Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522191 | AYTU | Modified release formulations containing drug—ion exchange resin complexes |
Jun, 2027
(3 years from now) | |
| US8062667 | AYTU | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
Drugs and Companies using CARBINOXAMINE MALEATE ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
KARBINAL ER family patents
2. Tuzistra Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790700 | AYTU | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8062667 | AYTU | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient
Market Authorisation Date: 30 April, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR family patents
3. Zolpimist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236285 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(8 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 19 December, 2008
Treatment: Treatment of transient insomnia
Dosage: SPRAY, METERED;ORAL
ZOLPIMIST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic